Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-LACC: Adjuvant Chemotherapy after CCRT in Locally Advanced Cervical Cancer
NCT02036164Phase 3
Key facts
- Status
- Unknown
- Start
- Jan 2014
- Primary completion
- Jan 2018
- Countries
- 1
- Modality
- DNA Intercalators/Alkylators
- Conditions
- Cervical Cancer (CC)
01
Overview
Phase 3, randomised, open-label trial of paclitaxel and carboplatin in Cervical Cancer (CC). Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We will investigate if ACT has survival benefit over CCRT alone.
Beyond the preview
Go deeper on NCT02036164.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036164.